X-c(=x)-x Containing (e.g., Carbonic Acid Ester, Thiocarbonic Acid Ester, Etc.) (x Is Chalcogen) Patents (Class 514/512)
  • Patent number: 10266484
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: April 23, 2019
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Martin Maier, Muthusamy Jayaraman, Shigeo Matsuda, Jayaprakash K. Nair, Kallanthottathil G. Rajeev, Akin Akinc, Thomas A. Baillie
  • Patent number: 9943500
    Abstract: The invention is a method and composition for treating a topical microbial infection in a subject. The method includes the step of administering a therapeutically effective amount of a polyether ionophore, or a therapeutically acceptable salt thereof, to the subject.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: April 17, 2018
    Assignee: Luoda Pharma Pty Ltd
    Inventor: Stephen Page
  • Patent number: 9713602
    Abstract: The present invention relates to a method for increasing the oxygen release efficiency of a hemoglobin-based blood substitute by using a phthalide compound, comprising the steps of: administering to a subject in need thereof the phthalide compound or co-administering to the subject in need thereof the phthalide compound along with the hemoglobin-based blood substitute, wherein the phthalide compound has an effect of increasing the oxygen release efficiency of the hemoglobin-based blood substitute, wherein the hemoglobin-based blood substitute can be fetal hemoglobin (HbF) or other Hb variants retaining two native ? subunits. The phthalide compound is used to substitute for or cooperate with 2,3-BPG, to play a role of a 2,3-BPG substitute, to act on the hemoglobin-based blood substitute to effectively substitute the function of normal hemoglobin in releasing oxygen to tissue cells, in order to maintain the cellular oxygenation level within a normal range.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: July 25, 2017
    Assignee: NATIONAL SUN YAT-SEN UNIVERSITY
    Inventors: Chia-Chen Wang, Wei-Ren Chen
  • Patent number: 9493430
    Abstract: The present invention provides biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds, isomers thereof, or pharmaceutically acceptable salts. The compounds of the invention show a CETP inhibitory effect that increases HDL-cholesterol levels and reduces LDL-cholesterol levels. Pharmaceutical compositions comprising the compounds are useful for the prevention or treatment of dyslipidemia or dyslipidemia-related diseases.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: November 15, 2016
    Assignee: Chong Kun Dang Pharmaceutical Corp.
    Inventors: Jae Kwang Lee, Jung Taek Oh, Jae Won Lee, Seo Hee Lee, Il-Hyang Kim, Jae Young Lee, Su Yeal Bae, Se Ra Lee, Yun Tae Kim
  • Patent number: 9272978
    Abstract: Hydroxy acid compound of substituted phenyl ester, preparation method and medical use thereof are provided. The title compound is shown in formula (I), Y?C1-4 straight carbon chain. The compound can release 2,6-diisopropylphenol rapidly under the action of enzymes in vivo, which has sedative, hypnotic and/or anesthetic effect. By protecting the hydroxyl group of 2, 6-diisopropylphenol in compound of formula (I), the first-pass metabolic activity of 2, 6-diisopropylphenol is reduced, so that the synthetic compound can be used for sedation, hypnosis, and/or anesthesia.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: March 1, 2016
    Assignee: West China Hospital, Sichuan University
    Inventors: Wensheng Zhang, Jun Yang, Jin Liu
  • Publication number: 20150133470
    Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
  • Patent number: 9024055
    Abstract: Acetaminophen conjugates are provided, which have an acetaminophen moiety covalently linked to a second moiety. The conjugates provided may have one or more advantageous properties, including increased water solubility as compared to acetaminophen, reduced toxicity profile as compared to acetaminophen and an altered pharmacokinetic profile. Formulations comprising the conjugates are also provided, as are methods of using the conjugates and kits comprising the conjugates.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: May 5, 2015
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Keith R. Bley, Bernd Jandeleit
  • Publication number: 20150119461
    Abstract: The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR? modulation such as diabetes.
    Type: Application
    Filed: January 9, 2015
    Publication date: April 30, 2015
    Inventors: Veera KONDA, Jan URBAN, Anuradha DESAI, Clinton J. DAHLBERG, Brian J. CARROLL
  • Patent number: 9012498
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: April 21, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Martin Maier, Muthusamy Jayaraman, Shigeo Matsuda, Narayanannair K. Jayaprakash, Kallanthottathil G. Rajeev, Akin Akinc, Thomas A. Baillie
  • Publication number: 20150086490
    Abstract: Described herein are compositions comprising a MMP-13 inhibitor, and methods of using the same.
    Type: Application
    Filed: October 2, 2014
    Publication date: March 26, 2015
    Inventors: Wei Wang, Virginia Barnes, Harsh M. Trivedi, Tao Xu
  • Publication number: 20150073015
    Abstract: The invention provides a process for the preparation of a compound of Formula 1, comprising coupling a carboxylic acid of Formula 2 with an aniline of Formula 3 in the presence of a coupling agent.
    Type: Application
    Filed: May 23, 2014
    Publication date: March 12, 2015
    Inventors: John DeMattei, Adam R. Looker, Bobbianna Neubert-Langille, Martin Trudeau, Stefanie Roeper, Michael P. Ryan, Dahrika Milfred Yap Guerette, Brian R. Krueger, Peter D.J. Grootenhuis, Fredrick F. Van Goor, Martyn C. Botfield, Gregor Zlokarnik
  • Patent number: 8901169
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: December 2, 2014
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Erik Fenster, Melissa Fleury, Adam D. Hughes
  • Patent number: 8883179
    Abstract: Described herein are compositions comprising a MMP-13 inhibitor, and methods of using the same.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: November 11, 2014
    Assignee: Colgate-Palmolive Company
    Inventors: Wei Wang, Virginia Barnes, Harsh M. Trivedi, Tao Xu
  • Publication number: 20140296241
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Application
    Filed: October 15, 2012
    Publication date: October 2, 2014
    Inventors: Irving W. Wainer, Ruin Moaddel, Michel Bernier, Carlos A. Zarate, Marc C. Torjman, Michael E. Goldberg, Mary J. Tanga
  • Publication number: 20140288142
    Abstract: The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metobolisms dysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent.
    Type: Application
    Filed: June 9, 2014
    Publication date: September 25, 2014
    Inventors: Nicoletta ALMIRANTE, Stefano BIONDI, Ennio ONGINI, Laura STORONI, Alessia NICOTRA
  • Publication number: 20140256770
    Abstract: The invention provides a process for the preparation of a compound of Formula 1, comprising coupling a carboxylic acid of Formula 2 with an aniline of Formula 3 in the presence of a coupling agent.
    Type: Application
    Filed: May 23, 2014
    Publication date: September 11, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: John DeMattei, Adam R. Looker, Bobbianna Neubert-Langille, Martin Trudeau, Stefanie Roeper, Michael P. Ryan, Dahrika Milfred Yap Guerette, Brian R. Krueger, Peter D.J. Grootenhuis, Fredrick F. Van Goor, Martyn C. Botfield, Gregor Zlokarnik
  • Publication number: 20140249105
    Abstract: Compounds, ceramide analogues, having a cyclic structure derived from cyclopropane, cyclobutane or cyclopentane, the ring bearing two chains consisting of an amide function. Each amide function is attached to the ring by the nitrogen atom of the function and carries a hydrocarbon chain derived from a fatty acid. The amide functions can be cis or trans relative to one another. Processes for the preparation of these novel compounds as well as pharmaceutical and/or cosmetic compositions containing them.
    Type: Application
    Filed: July 25, 2011
    Publication date: September 4, 2014
    Applicant: Diverchim
    Inventors: Jean-Louis Brayer, Natacha Frison, Benoit Folleas
  • Publication number: 20140243407
    Abstract: Acetaminophen conjugates are provided, which have an acetaminophen moiety covalently linked to a second moiety. The conjugates provided may have one or more advantageous properties, including increased water solubility as compared to acetaminophen, reduced toxicity profile as compared to acetaminophen and an altered pharmacokinetic profile. Formulations comprising the conjugates are also provided, as are methods of using the conjugates and kits comprising the conjugates.
    Type: Application
    Filed: September 21, 2012
    Publication date: August 28, 2014
    Applicant: Accorda Therapeutics, Inc.
    Inventors: Keith R. Bley, Bernd Jandeleit
  • Publication number: 20140235636
    Abstract: The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.
    Type: Application
    Filed: April 25, 2014
    Publication date: August 21, 2014
    Applicants: Cardioxyl Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: John P. Toscano, Art Sutton, Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost
  • Patent number: 8809391
    Abstract: The present invention relates to the use of 3-methyl-6-(1-methylethenyl)cyclohex-3-ene-1,2-diol, its isomers and derivatives, as a compound for Parkinson disease treatment, that can be used in medicine. The compound is highly active, low toxic and can be synthesized from available natural compound ?-pinene. 13 ex., 7 tables.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: August 19, 2014
    Assignee: OOO “Tomskaya Farmatsevticheskaya Fabrika”
    Inventors: Nariman Faridovich Salahutdinov, Tatiana Genrihovna Tolstikova, Alla Viktorovna Pavlova, Ekaterina Aleksandrovna Morozova, Irina Viktorovna Il'ina, Oleg Vasil'evich Ardashov, Konstantin Petrovich Volcho
  • Patent number: 8778991
    Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: July 15, 2014
    Assignee: XenoPort, Inc.
    Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
  • Patent number: 8716336
    Abstract: A smooth, dry-feeling, less-greasy, substantially-odorless, ecotoxicologically-safe, wax-based composition with a melting point above 25° C., comprising one or more wax components selected from dialkyl carbonates, dialkylene carbonates, and mixtures of two or more thereof; less than 10%, by weight, of water; and (c) optionally, one or more components selected from the group consisting of one or more wax or oil components selected from the group consisting of dialkyl ethers, dialkylene ethers, dicarboxylic acids, hydroxyfatty alcohols, and mixtures of two or more thereof, as well as one or more wax-like lipid components, other than those in previously listed, one or more other oil components, liquid at 20° C. and immiscible with water at 25° C.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: May 6, 2014
    Assignee: Cognis IP Management GmbH
    Inventors: Achim Ansmann, Ulrich Issberner, Stefan Bruening, Bettina Jackwerth, Daniele Hoffmann
  • Publication number: 20140066500
    Abstract: The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.
    Type: Application
    Filed: November 6, 2013
    Publication date: March 6, 2014
    Applicant: Reviva Pharmaceuticals, Inc.
    Inventors: Laxminarayan BHAT, Seema BHAT
  • Patent number: 8664247
    Abstract: The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: March 4, 2014
    Assignees: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Jan Scicinski, Bryan T. Oronsky, Robert Wardle, Louis Cannizzo, Nicholas A. Straessler
  • Publication number: 20140024709
    Abstract: The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 23, 2014
    Applicant: Reviva Pharmaceuticals, Inc.
    Inventors: Laxminarayan BHAT, Kouacou ADIEY
  • Patent number: 8632792
    Abstract: A cooling sensation agent composition with a prolonged cool sensation effect is provided comprising at least one compound selected from the group consisting of aceia or ketal derivatives of 3-(1-menthoxy)propan-1,2-diol represented by Formula (1), single or mixed carbonic esters ol one or two kinds ol alcohols represented by Formula (2), and carboxylic esters represented by Formula (4). A sensory stimulation agoni composition, a flavor or fragrance composition, a beverage or food product, a perfume or cosmetic product, a toiletry product, a daily utensil product or grocery, a fiber, a fiber product, a cloth or a medicine comprising the cooling sensation agent composition; a production method thereof; a cooling processing method of a fiber, fiber product or a cloth, comprising compounding the cooling sensation agent; and new compounds are also provided.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: January 21, 2014
    Assignee: Takasago International Corporation
    Inventors: Kenya Ishida, Takashi Aida, Tetsuya Yamamoto
  • Patent number: 8613940
    Abstract: Carbonates of anti-aging ingredients, in particular anti-oxidants and skin illuminating phenol ingredients, have been prepared as derivatives of these ingredients with enhanced physical properties. It has been demonstrated that these carbonates will hydrolyze under enzymatic catalysis to release the parent ingredient. In contrast, esters of the phenolic groups in many cases do not hydrolyze under the same conditions.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: December 24, 2013
    Assignee: Eastman Chemical Company
    Inventor: Neil Warren Boaz
  • Patent number: 8569371
    Abstract: Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical composition thereof.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: October 29, 2013
    Assignee: Pliva Hrvatska D.O.O.
    Inventors: Marina Ratkaj, Gustavo Frenkel
  • Publication number: 20130237573
    Abstract: A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: November 15, 2011
    Publication date: September 12, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventors: Bruce Anthony Dressman, Mark Donald Chappell, Adam Michael Fivush, Charles Howard Mitch, Paul Leslie Ornstein, Eric George Tromiczak, Tatiana Natali Vetman
  • Patent number: 8466197
    Abstract: The invention is directed to thiocarbonate compounds of Formula (I)-(III) and methods of treating atherosclerosis, neuropathy, nephropathy, retinopathy, inflammatory disorders, COPD, cardiovascular diseases, metabolic disorders, type I diabetes mellitus, type II diabetes mellitus, LADA, Wolfram Syndrome 1, Wolcott-Rallison syndrome, metabolic syndrome, dyslipidemia, hyperglycemia, or insulin resistance. The compounds of the invention are also useful for protecting pancreatic beta-cells and for reducing free fatty acids, triglycerides, advanced glycated end products, ROS, lipid peroxidation, tissue and plasma TNFalpha and IL6 levels, or for delaying or preventing cardiovascular complications associated with atherosclerosis.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: June 18, 2013
    Assignee: Genmedica Therapeutics SL
    Inventors: Julio Cesar Castro Palomino Laria, Luc Marti Clauzel, Antonio Zorzano Olarte, Silvia Garcia Vicente, Alec Mian
  • Patent number: 8455544
    Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: June 4, 2013
    Assignees: Reata Pharmaecuticals, Inc., Trustees of Dartmouth College
    Inventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Tadashi Honda, Robert M. Kral, Colin J. Meyer
  • Publication number: 20130116319
    Abstract: The present invention relates to the use of 3-methyl-6-(1-methylethenyl)cyclohex-3-ene-1,2-diol, its isomers and derivatives, as a compound for Parkinson disease treatment, that can be used in medicine. The compound is highly active, low toxic and can be synthesized from available natural compound ?-pinene.
    Type: Application
    Filed: December 23, 2010
    Publication date: May 9, 2013
    Applicant: OOO "TOMSKAYA FARMATSEVTICHESKAYA FABRIKA"
    Inventors: Nariman Faridovich Salahutdinov, Tatiana Genrihovna Tolstikova, Alla Viktorovna Pavlova, Ekaterina Aleksandrovna Morozova, Irina Viktorovna Il'ina, Oleg Vasil'evich Ardashov, Konstantin Petrovich Volcho
  • Publication number: 20130109639
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: November 1, 2012
    Publication date: May 2, 2013
    Inventors: Adam D. HUGHES, Erik FENSTER, Melissa FLEURY, Roland GENDRON
  • Publication number: 20130072522
    Abstract: The invention provides a process for the preparation of a compound of Formula 1, comprising coupling a carboxylic acid of Formula 2 with an aniline of Formula 3 in the presence of a coupling agent.
    Type: Application
    Filed: November 6, 2012
    Publication date: March 21, 2013
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventor: Vertex Pharmaceuticals Incorporated
  • Publication number: 20130053418
    Abstract: The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.
    Type: Application
    Filed: August 24, 2012
    Publication date: February 28, 2013
    Inventors: Jan Scicinski, Bryan T. Oronsky, Robert Wardle, Louis Cannizzo, Nicholas A. Straessler
  • Publication number: 20120302634
    Abstract: The invention relates to a silicone-free skin protection composition, in particular a composition to protect against cold, containing the components a.) at least one oil with a pour point in accordance with DIN ISO 30 16 of ??10° C., b.) at least one polyol c.) at least one emulsifier d.) optionally at least one wax, where the viscosity difference in the temperature interval from +4° C. to +50° C. of highest and lowest viscosity of the skin protection composition has a value in the range from 0 to ?20 000 mPas.
    Type: Application
    Filed: June 12, 2012
    Publication date: November 29, 2012
    Applicant: Evonik Stockhausen GmbH
    Inventors: Marcel VEEGER, Petra Allef
  • Publication number: 20120294915
    Abstract: Described herein are compositions comprising a MMP-13 inhibitor, and methods of using the same.
    Type: Application
    Filed: December 21, 2010
    Publication date: November 22, 2012
    Applicant: Colgate-Palmolive Company
    Inventors: Wei Wang, Virginia Barnes, Harsh M. Trivedi, Tao Xu
  • Patent number: 8293786
    Abstract: Described herein are cannabidiol prodrugs, methods of making cannabidiol prodrugs, formulations comprising cannabidiol prodrugs and methods of using cannabidiols. One embodiment described herein relates to the transdermal or topical administration of a cannabidiol prodrug for treating and preventing diseases and/or disorders.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: October 23, 2012
    Assignee: Alltranz Inc.
    Inventors: Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffrey Lynn Howard, Stan Lee Banks
  • Publication number: 20120251608
    Abstract: A cationic star polymer is disclosed of the general formula (1): I??P?]w???(1), wherein w? is a positive number greater than or equal to 3, I? is a dendritic polyester core covalently linked to w? independent peripheral linear cationic polymer chains P?. Each of the chains P? comprises a cationic repeat unit comprising i) a backbone functional group selected from the group consisting of aliphatic carbonates, aliphatic esters, aliphatic carbamates, aliphatic ureas, aliphatic thiocarbamates, aliphatic dithiocarbonates, and combinations thereof, and ii) a side chain comprising a quaternary amine group. The quaternary amine group comprises a divalent methylene group directly covalently linked to i) a positive charged nitrogen and ii) an aromatic ring.
    Type: Application
    Filed: December 21, 2011
    Publication date: October 4, 2012
    Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Daniel Joseph Coady, Amanda Catherine Engler, Kazuki Fukushima, James Lupton Hedrick, Jeremy Pang Kern Tan, Yi Yan Yang
  • Publication number: 20120232031
    Abstract: Described herein are injectable formulations for intra-articular or peri-articular administration, wherein the formulation is administered to treat joint pain. An injectable formulation for intra-articular or peri-articular administration disclosed herein comprises a therapeutically-effective amount of a leukotriene synthesis inhibitor compound formulated for intra-articular or peri-articular administration.
    Type: Application
    Filed: October 19, 2010
    Publication date: September 13, 2012
    Applicant: Panmira Pharmaceuticals, LLC
    Inventors: John Howard Hutchinson, Petpiboon Peppi Prasit, Isabelle Marguerite Dearmond
  • Publication number: 20120208850
    Abstract: The invention relates to methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid (1,3PDS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 1,3PDS, either in vitro or in vivo. The invention also relates to sulfonate ester prodrugs of 1,3PDS as well as Gemini dimmers and oligomers of 1,3PDS for the prevention or treatment of associated diseases and conditions.
    Type: Application
    Filed: August 6, 2010
    Publication date: August 16, 2012
    Applicant: BELLUS HEALTH INC.
    Inventors: Xianqi Kong, Nigel Levens, Abderrahim Bouzide, Stephane Ciblat, Richard Frenette, Johanne Renaud
  • Publication number: 20120172426
    Abstract: The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.
    Type: Application
    Filed: July 1, 2011
    Publication date: July 5, 2012
    Applicant: REVIVA PHARMACEUTICALS, INC.
    Inventors: Laxminarayan Bhat, Kouacou Adiey
  • Publication number: 20120157523
    Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.
    Type: Application
    Filed: October 14, 2011
    Publication date: June 21, 2012
    Applicant: XenoPort, Inc.
    Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
  • Publication number: 20120149769
    Abstract: The invention is directed to thiocarbonate compounds of Formula (I)-(III) and methods of treating atherosclerosis, neuropathy, nephropathy, retinopathy, inflammatory disorders, COPD, cardiovascular diseases, metabolic disorders, type I diabetes mellitus, type II diabetes mellitus, LADA, Wolfram Syndrome 1, Wolcott-Rallison syndrome, metabolic syndrome, dyslipidemia, hyperglycemia, or insulin resistance. The compounds of the invention are also useful for protecting pancreatic beta-cells and for reducing free fatty acids, triglycerides, advanced glycated end products, ROS, lipid peroxidation, tissue and plasma TNFalpha and IL6 levels, or for delaying or preventing cardiovascular complications associated with atherosclerosis.
    Type: Application
    Filed: September 16, 2011
    Publication date: June 14, 2012
    Applicant: GENMEDICA THERAPEUTICS SL
    Inventors: Julio Cesar Castro Palomino Laria, Luc Marti Clauzel, Antonio Zorzano Olarte, Silvia Garcia Vicente, Alec Mian
  • Publication number: 20120108592
    Abstract: A new class of salicylanilides is described. These compounds show strong activity against hepatitis viruses.
    Type: Application
    Filed: October 28, 2011
    Publication date: May 3, 2012
    Inventors: J. Edward Semple, Jean-Francois Rossignol
  • Publication number: 20120059056
    Abstract: Carbonates of anti-aging ingredients, in particular anti-oxidants and skin illuminating phenol ingredients, have been prepared as derivatives of these ingredients with enhanced physical properties. It has been demonstrated that these carbonates will hydrolyze under enzymatic catalysis to release the parent ingredient. In contrast, esters of the phenolic groups in many cases do not hydrolyze under the same conditions.
    Type: Application
    Filed: December 22, 2010
    Publication date: March 8, 2012
    Applicant: EASTMAN CHEMICAL COMPANY
    Inventor: Neil Warren Boaz
  • Patent number: 8129429
    Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: March 6, 2012
    Assignees: Reata Pharmaceuticals, Inc., Trustees of Dartmouth College
    Inventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Tadashi Honda, Robert M. Kral, Colin J. Meyer
  • Publication number: 20120046272
    Abstract: The present invention describes a series of therapeutically active compounds of formula I, X—Y—Z??(I) that are useful for treating a disorder in a mammal. In the formula I, X and Z, which may be same or different, are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic group or substituted or unsubstituted heterocyclylalkyl; and Y is a linker selected from —O—, —S—, —NH—, —(CH2)n—, —CO—, —CONRa—, —NRaCO—, —NRaCOO—, —COO—, —CONRaCO—, —CONRaCOO— and —COOCOO—.
    Type: Application
    Filed: August 19, 2011
    Publication date: February 23, 2012
    Applicant: GRUNENTHAL GMBH
    Inventor: Ramesh SESHA
  • Patent number: 8119667
    Abstract: Novel fenicol compounds having useful properties as antibiotic prodrugs, are provided, together with methods of making and using these new compounds.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: February 21, 2012
    Assignee: Schering-Plough Animal Health Corporation
    Inventors: Tomasz W. Glinka, Dale Edward Shuster, Chander Shekher Celly, Robert D. Simmons, Jason Zhang
  • Publication number: 20120034174
    Abstract: The present invention provides a surfactant product in the form of a solid comprising a surfactant, sodium carbonate and cream of tartar.
    Type: Application
    Filed: February 19, 2010
    Publication date: February 9, 2012
    Inventors: Mark Constantine, Margaret Joan Constantine, Helen Elizabeth Ambrosen